Venus Remedies Limited, a Chandigarh based pharmaceutical firm engaged in the manufacture of highly sophisticated oncology formulations & latest generation Cephalosporin injectables, has successfully launched its brand "Ronem", a premium antibacterial for critical care.

The constant endeavour of the company to stay ahead of all on all fronts has made it possible for the company to launch this premium brand under its Parenteral Specialty sales division. Venus is the only company in India to manufacture and market this Meropenem' Injection. The only other company marketing this formulation is AstraZeneca, which is importing this injection. This latest formulation of the Carbapenem group, provides a sure shot remedy for any kind of bacterial infection as it is a broad spectrum antibiotic, effective against both Gram Negative & Gram Positive bacteria including nosocomial isolates resistant to Ceftazidime, Cefotaxime, Ceftriaxone and Piperacillin and Gentamycin. It is most useful in case of Bacterial Septicaemia, Bacterial Meningitis, Cystic Fibrosis, febrile neutropenia, nosocomial pneumonia.

This new formulation is a latest generation Carbapenem, a sub group under the largest segment of antibiotics i.e. the anti-infective segment, with a market worth US $18.7 billion in the world. The new formulation is targeted at the niche market of the top 1000 surgeons of the country who will have access to this critical care remedy for the patients undergoing surgery and kept under observation in ICU. This is a very high value formulation with sure shot results under emergency situations and is likely to build up a market of nearly Rs 60 million in its launch year i.e. 2005.